Introduction {#Sec1}
============

Although chemotherapy-induced nausea and vomiting (CINV) are not life-threatening adverse events, they can nevertheless adversely affect the quality of life, and thus control of CINV plays a key role in the treatment of cancer patients undergoing chemotherapy. Antiemetic guidelines \[[@CR1]--[@CR3]\] have defined the emetic risk of antineoplastic agents \[[@CR4]\] as high (\>90% emetic risk), moderate (30--90%), low (10--30%), and minimal (\<10%), the figures in parentheses representing the percentage of patients having emetic episode(s) when no prophylactic antiemetic protection provided. CINV prophylaxis for highly emetogenic chemotherapy (HEC) includes a three-drug regimen: a 5-HT~3~ receptor antagonist (5-HT~3~RA), dexamethasone and a neurokinin-1 (NK-1) receptor antagonist; for moderately emetogenic chemotherapy (MEC), standard prophylaxis includes a two-drug regimen: a 5-HT~3~RA and dexamethasone or methyl-prednisone, both given on the day of chemotherapy, with the administration of either dexamethasone or a 5-HT~3~RA for 3-4 days after treatment. Currently, standard antiemetic therapy in patients with lymphomas undergoing MEC is a combination therapy with a 5-HT~3~RA and steroids \[[@CR5]\].

The first generation 5-HT~3~RAs (ondansetron, granisetron, dolasetron, and tropisetron) have demonstrated considerable efficacy in preventing acute (0--24 h after chemotherapy) CINV which is mostly serotonin related, but there is no clinical evidence to justify their use beyond 24 h after chemotherapy for prevention of delayed (24--120 h after chemotherapy), in part substance P-related, emesis \[[@CR6]\]. Palonosetron is a second-generation 5-HT~3~RA, and is approved by FDA for treatment of delayed emesis \[[@CR7]\]. The characteristics of palonosetron distinguish it from other 5-HT~3~RAs \[[@CR7], [@CR8]\]. In particular, it has a prolonged half-life (∼40 h) and a high binding affinity (approximately 2,500-fold higher than that of serotonin), in addition showing allosteric interactions and positive cooperativity with the 5-HT~3~ receptor \[[@CR9], [@CR10]\]. The actual role of palonosetron in comparison with the other available 5-HT~3~RAs is discussed controversially in all three main antiemetic guidelines. There is some evidence that palonosetron may be superior to first generation 5-HT~3~RAs in providing control of both nausea and vomiting in patients undergoing either MEC or HEC \[[@CR11]--[@CR15]\]. Due to its unique pharmacological characteristics \[[@CR7]--[@CR10]\], palonosetron can protect patients from CINV during the overall emetic risk period after chemotherapy (0--120 h), even when employed without corticosteroids.

The aim of this multicentre, open-label, non-randomized, phase II study was to evaluate the efficacy and safety of a single intravenous bolus of palonosetron (0.25 mg) for the prevention of CINV during 5 days post-chemotherapy in patients with aggressive non-Hodgkin\'s lymphoma (NHL) treated with anthracycline-containing regimens.

Patients and methods {#Sec2}
====================

This study (EudraCT number 2006-003189-33, NCT number 01018758) was conducted according to the Declaration of Helsinki and Good Clinical Practice guidelines. The study protocol was approved by local ethics committees, and all patients gave written informed consent to participate before study entry. Patients with histologically or cytologically confirmed aggressive NHL, at any stage, were eligible. Patients were required to be \>18 years of age, with an Eastern Cooperative Oncology Group performance status of zero to one and acceptable hepatic and renal functions, scheduled to receive at least one moderately emetogenic agent on day 1, according to the modified Hesketh classification \[[@CR4], [@CR16]\]. Patients with diagnosis of Hodgkin\'s lymphoma or leukemia, and candidates for multiple day/high-dose chemotherapy or bone marrow/peripheral blood stem cell transplantation were excluded.

Treatment plan {#Sec3}
--------------

Patients received a single intravenous bolus of palonosetron (0.25 mg), over 30 s, beginning 30 min before chemotherapy on day 1. Patients were assessed from day 1 throughout day 5 after the start of chemotherapy, and the antiemetic response was evaluated during the acute, delayed and overall phases, as well on each day.

Patients were followed for safety and tolerability, and adverse events were considered by the investigator to be possibly, probably or definitely related to study medication until the start of the next chemotherapy cycle. Patients were asked to fill in a diary beginning on day 1 until day 5, reporting the occurrence and severity of emesis and nausea episodes, as well as the use of rescue medication. At the end of the study, patient global satisfaction with antiemetic therapy was measured using a visual analogue scale (VAS). After chemotherapy, rescue medication including dexamethasone and/or metoclopramide for nausea and vomiting was permitted upon request of the patient and recorded in patient\'s diary.

Study endpoints and assessments {#Sec4}
-------------------------------

The primary endpoint was the overall rate of patients achieving a complete response (CR), defined as no emetic episodes and no use of rescue medication during the overall phase. Secondary endpoints were evaluated during the acute, delayed and overall phases and included CR rate during the acute and delayed phases, rate of complete control (CC; defined as CR with a maximum grade of mild nausea), percentage of patients experiencing emesis and nausea (severity graded according to Likert scale), patient global satisfaction with antiemetic therapy, as measured by VAS, and safety profile of palonosetron. Severity of nausea was graded according to Likert scale: 0-none, 1-mild; 2-moderate; 3-severe, according to subjective assessment by each patient.

Statistical analysis {#Sec5}
--------------------

The efficacy of palonosetron was evaluated upon a one-stage Fleming study design for determination of response rates based on a single treatment group \[[@CR17]\].

A sample size of 77 patients was estimated using the exact method (binomial) and assuming that π = 20 (null hypothesis) is the largest value for the proportion of responders for which the treatment is considered ineffective, and π = 35 (alternative hypothesis) the smallest value for the proportion of responders for which the treatment is considered effective, with a probability of type 1 error equal to 0.05 (one-tail), and a power of 90%. Eighty-five patients were planned for enrolment, considering a loss of 10% (lost to follow-up, withdrawal of informed consent, administrative reasons). The safety cohort included all patients who received at least one dose of the study medication after registration.

Results {#Sec6}
=======

Between June 2006 and July 2008, a total of 91 patients with NHL were prospectively recruited by ten Italian centers belonging to the Gruppo Italiano per lo Studio dei Linfomi (GISL). Five patients were considered not eligible: four were low grade NHL and one patient had an ECOG = 3. Demographic and baseline data of the 86 evaluable patients are shown in Table [1](#Tab1){ref-type="table"}. The majority of patients had diffuse large B cell lymphoma (77.9%), stage III and IV disease (67.4%) and received CHOP+/−R (cyclophosphamide, doxorubicin, vincristine and prednisone, ± rituximab) chemotherapy (74.4%). Table 1Patient characteristicsCharacteristicPopulation (*N* = 86)*N* (%)Age (years) Median65 Range20--87Male gender47 (54.6)ECOG performance status 0--157 (66.3) 229 (33.7)Histology DLBCL67 (77.9) FL grade III8 (9.3) PTCL3 (3.5) ALCL3 (3.5) MCL2 (2.3) MZL2 (2.3) BL1 (1.2)Stage I12 (14.0) II16 (18.6) III29 (33.7) IV29 (33.7)Chemotherapy regimen R-CHOP40 (46.5) CHOP24 (27.9) R-COMP13 (15.1) Other^a^9 (10.5)*DLBCL* diffuse large B cell lymphoma, *FL* follicular lymphoma, *PTCL* peripheral T cell lymphoma, *ALCL* anaplastic large cell lymphoma, *MCL* mantle cell lymphoma, *MZL* marginal zone lymphoma, *BL* Burkitt\'s lymphoma, *CHOP* cyclophosphamide, doxorubicin, vincristine, prednisone, *R-CHOP* rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, *R-COMP* rituximab, cyclophosphamide, vincristine, liposomal doxorubicin, prednisone^a^Doxorubicin based regimen

Efficacy {#Sec7}
--------

Regarding the primary endpoint, CR was observed in 74 of 86 patients (86.0%) during the overall phase. CR during the acute and delayed phases was 90.7% and 88.4% (Fig. [1](#Fig1){ref-type="fig"}), respectively. The CC was 89.5% during the acute and 84.9% during the delayed phase was; the overall CC was 82.6% (Table [2](#Tab2){ref-type="table"}). Table [2](#Tab2){ref-type="table"} shows the proportion of patients who did not experience both emesis and nausea, during the delayed and overall phases and on individual days. During the overall study period, the emesis-free rate was 88.4%, while the nausea-free rate was 74.4%; no patient experienced severe nausea. The median patient global satisfaction with antiemetic therapy was 8.0 (range, 1--10). Fig. 1Complete response rate during the overall (0--120 h), acute (0--24 h), and delayed (24--120 h) phasesTable 2Emesis-free and nausea-free rates during individual days, the delayed (24--120 h) and overall phases (0--120 h) and complete control during the acute (0--24 h), delayed and overall phasesPopulation (*N* = 86)*N* (%)Emesis free^a^ Day 179 (91.9) Day 279 (91.9) Day 383 (96.5) Day 486 (100) Day 584 (97.7) Delayed phase77 (89.5) Overall study period76 (88.4)Nausea free^b^ Day 173 (84.9) Day 270 (81.4) Day 377 (89.5) Day 482 (95.3) Day 582 (95.3) Delayed phase65 (75.6) Overall study period64 (74.4)Complete control^c^ Acute phase77 (89.5) Delayed phase73 (84.9) Overall study period71 (82.6)^a^No episodes of vomiting^b^No episodes of nausea of any grading^c^No vomiting episodes, no use of rescue medication, and no more than mild nausea

Tolerability {#Sec8}
------------

Palonosetron was well tolerated and no patient experienced a severe adverse event. The most common grade 1--2 adverse events were constipation (7.0%), headache (5.8%), asthenia (7.0%) and dizziness (1.2%). No grade 3 and 4 adverse events and no significant changes in laboratory tests or vital signs were observed during the study period.

Discussion {#Sec9}
==========

The results of this multicentre clinical trial demonstrate that a single dose of palonosetron (0.25 mg) before chemotherapy, without supplementing with additional dexamethasone, is effective and well tolerated by patients with aggressive NHL treated with MEC. Uncontrolled emesis associated with chemotherapy is sometimes such a negative experience that it may even lead to refusal by the patient to undergo potentially life-saving treatments for their malignancy \[[@CR18], [@CR19]\]. Currently, antiemetic guidelines \[[@CR1]--[@CR3]\] for MEC suggest the use of a 5-HT~3~RA and dexamethasone on day 1, followed by dexamethasone on days 2 and 3 to prevent delayed CINV. This recommendation stems from clinical evidence showing that corticosteroids increase the effect of other antiemetics \[[@CR20]\] such as low-dose and high-dose metoclopramide \[[@CR21]\], first generation 5-HT~3~RAs \[[@CR22], [@CR23]\], and a NK-1 receptor antagonist \[[@CR24], [@CR25]\]. Clinicians, however, have some concerns about the use of dexamethasone in clinical practice because of its potential side effects \[[@CR5]\]. Palonosetron, due to its unique pharmacological characteristics \[[@CR6]--[@CR10]\], may be of benefit in avoiding or minimizing the use of steroids \[[@CR26], [@CR27]\].

Two previous studies have assessed the efficacy of first generation 5-HT~3~RA (ondansetron and granisetron) in malignant lymphoma patients undergoing CHOP like chemotherapy: one study \[[@CR28]\] compared ondansetron and metoclopramide, while Numbenjapon et al. compared granisetron (GRAN) and metoclopramide \[[@CR29]\], both combined with corticosteroid (CS). Antiemetic prophylaxis in the OND study was: OND 8 mg/methylprednisolone 80 mg i.v. before chemotherapy and OND 8 mg p.o. after 8 h and at bedtime. OND 8 mg tid days 2--3, and 8 mg tid prn days 4--5, and prednisolone 75--100 mg qds days 2--5. In the acute phase, no emesis was registered in 92%, and no nausea in 79% of the OND/CS-treated group. The ultimate aim---neither nausea nor emesis---was reached in 77% of OND/CS-treated patients. The control of delayed nausea was obtained in 81% of patients \[[@CR28]\]. Antiemetic prophylaxis in the Numbenjapon study \[[@CR29]\] was GRAN 1 mg with 8 mg dexamethasone before chemotherapy and GRAN 1 mg daily on days 2--5. In the acute phase patients achieved a control response of 87.5% during the acute phase and 95.8% during the delayed phase.

In the present trial, most patients were treated with CHOP+/−R (cyclophosphamide 750 mg/sqm i.v., doxorubicin 50 mg/sqm i.v. and vincristine 1.4 mg/sqm i.v. on day 1, prednisone 100 mg daily o.s. for 5 days ±/− rituximab 375 mg/sqm i.v. on day 1), which is considered the standard of care for aggressive NHL patients \[[@CR30]\]. With a similar chemotherapeutic regimen, the GELA (Groupe d\'Etude des Lymphomes de l\'Adulte) trial \[[@CR30]\], which assessed the additional of rituximab to the CHOP regimen, has shown an incidence of nausea and vomiting of any grade of 40--48%, with 4--8% of grades 3--4. In our trial, the incidence of nausea of any grade ranged from 4.7% to 18.6%, and the rate of vomiting of any grade ranged from 0% to 8.1% during the 5 days of observation. It is also worthwhile noting that this population is younger and at a higher risk of emesis, than that of the GELA trial. The primary endpoint of our study was reached since 86.0% of patients achieved a CR during the overall study period. The secondary endpoints were also met as the percentage of CC in the acute and late phases was 89.5% and 84.9%, respectively.

Palonosetron was well tolerated and the incidence and severity of adverse events were low. The modality of administration by bolus infusion over 30″, differently than first generation 5-HT3RAs, allows to reduce the overall treatment time and the staff costs. Finally, the antiemetic efficacy being equal, a single dose of palonosetron is less expensive than several infusions of first generation antagonists. The weakness of our study is absence of dexamethasone-containing control arm, but recent randomized trials \[[@CR31], [@CR32]\] have investigated if the use of palonosetron might provide the opportunity to reduce the total corticosteroid dose with no loss of efficacy in delayed MEC, in patients receiving chemotherapeutic regimens which don't include steroid administration.

Both studies demonstrated that a reduced dexamethasone dosing regimen offers high and similar protection as 3-day dosing, as demonstrated by the equivalent complete response rates in the 5-day observation interval \[[@CR31], [@CR32]\].

This was the first trial, which demonstrated the efficacy of a single dose of palonosetron in control CINV in patients receiving MEC regimen containing steroids.
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